Get the Stockscreener App
0.7964
9.08%
0.0663
After Hours:
.80
0.0036
+0.45%
Talphera Inc stock is traded at $0.7964, with a volume of 427.47K.
It is up +9.08% in the last 24 hours and down -17.02% over the past month.
Talphera Inc. is a pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company's nafamostat product candidates include Niyad and LTX-608. Its portfolio consists of nafamostat product candidates and pre-filled syringe product candidates.
See More
Previous Close:
$0.7301
Open:
$0.74
24h Volume:
427.47K
Relative Volume:
1.43
Market Cap:
$37.12M
Revenue:
$28,000
Net Income/Loss:
$-12.46M
P/E Ratio:
-2.1069
EPS:
-0.378
Net Cash Flow:
$-11.18M
1W Performance:
+3.35%
1M Performance:
-17.02%
6M Performance:
-11.72%
1Y Performance:
+23.72%
1-Day Range:
$0.73
$0.8012
1-Week Range:
$0.7016
$0.8762
52-Week Range:
$0.38
$1.57
Talphera Inc Stock (TLPH) Company Profile
Compare TLPH vs TAK, ZTS, HLN, TEVA, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TLPH
Talphera Inc
|
0.7964 | 34.03M | 28,000 | -12.46M | -11.18M | -0.378 |
TAK
Takeda Pharmaceutical Co Adr
|
18.29 | 56.99B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
116.71 | 48.94B | 9.47B | 2.67B | 2.28B | 6.0218 |
HLN
Haleon Plc Adr
|
9.74 | 43.30B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.46 | 33.94B | 17.41B | 1.43B | 1.00B | 1.2182 |
UTHR
United Therapeutics Corp
|
541.60 | 23.31B | 3.18B | 1.33B | 1.04B | 27.90 |
Talphera Inc Stock (TLPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Jul-20-20 | Downgrade | Credit Suisse | Neutral → Underperform |
| Nov-11-19 | Downgrade | Credit Suisse | Outperform → Neutral |
| Aug-05-19 | Resumed | Credit Suisse | Outperform |
| Jul-10-19 | Resumed | Credit Suisse | Outperform |
| Apr-24-19 | Resumed | B. Riley FBR | Buy |
| Feb-15-19 | Initiated | Credit Suisse | Outperform |
| Oct-23-18 | Initiated | B. Riley FBR | Buy |
| Oct-13-17 | Downgrade | Jefferies | Buy → Hold |
| Oct-13-17 | Reiterated | RBC Capital Mkts | Outperform |
| Jul-14-17 | Resumed | Jefferies | Buy |
| Sep-15-16 | Reiterated | ROTH Capital | Buy |
| Aug-05-16 | Downgrade | Stifel | Buy → Hold |
| Oct-30-15 | Upgrade | Jefferies | Hold → Buy |
| Oct-05-15 | Reiterated | ROTH Capital | Buy |
| Sep-02-15 | Initiated | H.C. Wainwright | Buy |
| Jul-10-15 | Resumed | ROTH Capital | Buy |
| May-06-15 | Reiterated | Mizuho | Neutral |
| May-05-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-10-15 | Reiterated | RBC Capital Mkts | Outperform |
| Mar-09-15 | Downgrade | Mizuho | Buy → Neutral |
View All
Talphera Inc Stock (TLPH) Latest News
Angotti buys Talphera (TLPH) shares worth $124,999 - Investing.com
Talphera (TLPH) CEO boosts stake with 213,310-share open-market buy - Stock Titan
Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 - Bitget
Talphera (TLPH) registers resale of up to 7.04M shares from private placement - Stock Titan
Talphera (TLPH) Reports Progress in Nafamostat Study and Financi - GuruFocus
Talphera: Q4 Earnings Snapshot - theheraldreview.com
Talphera, Inc. (Formerly AcelRx) 2025 Annual Report: Business Overview, Key Risks, and Regulatory Challenges in Specialty Pharmaceuticals - Minichart
Talphera Q4 2025 & Investor Day Earnings Call Transcript - MarketBeat
Talphera files prospectus for resale of up to 30.9M shares by selling stockholders - MSN
Talphera Inc. Q4 & Fiscal 2025 Financial Results: Revenue & Net Loss ReportNews and Statistics - IndexBox
[10-K] TALPHERA, INC. Files Annual Report - Stock Titan
Talphera 2025 10-K: Revenue $0.028M, Net Loss $14.3M - TradingView
TLPH: Net loss increased to $14.3M in 2025; urgent capital needs and Nasdaq delisting risk persist - TradingView
Earnings call transcript: Talphera Inc. Q4 2025: Stock Declines Amid Study Delays - Investing.com India
Talphera, Inc. (NASDAQ: TLPH) 2026 Financial Results and Company Information Overview - Minichart
Talphera, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
Talphera Inc (TLPH) Reports Q4 Earnings - AlphaStreet
Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - Bitget
Talphera: Fourth Quarter Financial Results Overview - Bitget
Rate Hike: Can Talphera Inc grow without external fundingTake Profit & Comprehensive Market Scan Reports - baoquankhu1.vn
TLPH PE Ratio & Valuation, Is TLPH Overvalued - Intellectia AI
Talphera outlines accelerated NEPHRO CRRT study timeline with completion targeted by end of 2025, supported by new site activations and $14.8M financing - MSN
Street Watch: Can Talphera Inc keep up with sector leaders2026 Trends & Capital Efficiency Focused Strategies - baoquankhu1.vn
Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026 - ChartMill
Nantahala Capital-linked holders in Talphera (TLPH) acquire 4,266,211 pre-funded warrants - Stock Titan
Talphera, Inc. (formerly AcelRx Pharmaceuticals) Files Form 8-K – Company Details and SEC Filing Information - Minichart
Talphera (NASDAQ: TLPH) adds $4.1M in third private placement - Stock Titan
Talphera Receives Nasdaq Notice on Minimum Bid Price - The Globe and Mail
Talphera, Inc. 8-K SEC Filing: Company Information, Address, NASDAQ Listing & Key Details (March 11, 2026) - Minichart
Talphera Received Notice of Noncompliance - TradingView
Talphera (NASDAQ: TLPH) faces Nasdaq minimum bid-price deficiency notice - Stock Titan
Sentiment Recap: Can Talphera Inc grow without external funding2025 Big Picture & Weekly High Return Stock Opportunities - baoquankhu1.vn
Aug Sentiment: Is Talphera Inc a top pick in the sectorJuly 2025 Selloffs & Daily Profit Maximizing Tips - baoquankhu1.vn
Analysts’ Opinions Are Mixed on These Healthcare Stocks: CalciMedica (CALC) and Talphera (TLPH) - The Globe and Mail
TLPH Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Talphera (TLPH) Achieves Key Enrollment Milestone in Clinical Tr - GuruFocus
Talphera reaches 50% enrollment in CRRT anticoagulant trial - Investing.com
Talphera announces 50% enrollment milestone in ongoing Nephro-Crrt registrational trial - marketscreener.com
Talphera Announces 50% Enrollment Milestone In Ongoing Nephro-Crrt Registrational Trial - TradingView
Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial - marketscreener.com
Dow Update: What is Talphera Incs 5 year growth outlookMarket Growth Summary & High Accuracy Swing Entry Alerts - baoquankhu1.vn
Insider Buying: Talphera (NASDAQ:TLPH) Insider Acquires $28,350.00 in Stock - Defense World
Insider Buying: Talphera (NASDAQ:TLPH) CFO Buys $36,450.00 in Stock - Defense World
Talphera (NASDAQ:TLPH) Insider Purchases $28,350.00 in Stock - Defense World
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Talphera CFO Asadorian buys $36k in TLPH stock By Investing.com - Investing.com South Africa
Aslam Shakil buys $28k in Talphera (TLPH) stock By Investing.com - Investing.com UK
Talphera (TLPH) CEO Angotti buys $85k in shares - Investing.com
Talphera (TLPH) CEO Angotti buys $85k in shares By Investing.com - Investing.com Australia
Talphera CFO Asadorian buys $36k in TLPH stock - Investing.com
Talphera’s Dasu Badri N buys $28,430 in shares - Investing.com Nigeria
Talphera Inc Stock (TLPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.12%
1.13%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):